Cargando…

Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience

BACKGROUND: After the completion of therapy, patients with localized rhabdomyosarcoma (RMS) are subjected to intensive radiological tumor surveillance. However, the clinical benefit of this surveillance is unclear. This study retrospectively analyzed the value of off‐therapy surveillance by comparin...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaarwerk, Bas, Mallebranche, Coralie, Affinita, Maria C., van der Lee, Johanna H., Ferrari, Andrea, Chisholm, Julia C., Defachelles, Anne‐Sophie, De Salvo, Gian Luca, Corradini, Nadège, Minard‐Colin, Veronique, Morosi, Carlo, Brisse, Hervé J., McHugh, Kieran, Bisogno, Gianni, van Rijn, Rick R., Orbach, Daniel, Merks, Johannes H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027831/
https://www.ncbi.nlm.nih.gov/pubmed/31750944
http://dx.doi.org/10.1002/cncr.32603
_version_ 1783498914222047232
author Vaarwerk, Bas
Mallebranche, Coralie
Affinita, Maria C.
van der Lee, Johanna H.
Ferrari, Andrea
Chisholm, Julia C.
Defachelles, Anne‐Sophie
De Salvo, Gian Luca
Corradini, Nadège
Minard‐Colin, Veronique
Morosi, Carlo
Brisse, Hervé J.
McHugh, Kieran
Bisogno, Gianni
van Rijn, Rick R.
Orbach, Daniel
Merks, Johannes H. M.
author_facet Vaarwerk, Bas
Mallebranche, Coralie
Affinita, Maria C.
van der Lee, Johanna H.
Ferrari, Andrea
Chisholm, Julia C.
Defachelles, Anne‐Sophie
De Salvo, Gian Luca
Corradini, Nadège
Minard‐Colin, Veronique
Morosi, Carlo
Brisse, Hervé J.
McHugh, Kieran
Bisogno, Gianni
van Rijn, Rick R.
Orbach, Daniel
Merks, Johannes H. M.
author_sort Vaarwerk, Bas
collection PubMed
description BACKGROUND: After the completion of therapy, patients with localized rhabdomyosarcoma (RMS) are subjected to intensive radiological tumor surveillance. However, the clinical benefit of this surveillance is unclear. This study retrospectively analyzed the value of off‐therapy surveillance by comparing the survival of patients in whom relapse was detected by routine imaging (the imaging group) and patients in whom relapse was first suspected by symptoms (the symptom group). METHODS: This study included patients with relapsed RMS after the completion of therapy for localized RMS who were treated in large pediatric oncology hospitals in France, the United Kingdom, Italy, and the Netherlands and who were enrolled in the International Society of Paediatric Oncology Malignant Mesenchymal Tumor 95 (1995‐2004) study, the Italian Paediatric Soft Tissue Sarcoma Committee Rhabdomyosarcoma 96 (1996‐2004) study, or the European Paediatric Soft Tissue Sarcoma Study Group Rhabdomyosarcoma 2005 (2005‐2013) study. The survival times after relapse were compared with a log‐rank test between patients in the imaging group and patients in the symptom group. RESULTS: In total, 199 patients with relapsed RMS were included: 78 patients (39.2%) in the imaging group and 121 patients (60.8%) in the symptom group. The median follow‐up time after relapse was 7.4 years (interquartile range, 3.9‐11.5 years) for survivors (n = 86); the 3‐year postrelapse survival rate was 50% (95% confidence interval [CI], 38%‐61%) for the imaging group and 46% (95% CI, 37%‐55%) for the symptom group (P = .7). CONCLUSIONS: Although systematic routine imaging is the standard of care after RMS therapy, the majority of relapses were detected as a result of clinical symptoms. This study found no survival advantage for patients whose relapse was detected before the emergence of clinical symptoms. These results show that the value of off‐therapy surveillance is controversial, particularly because repeated imaging may also entail potential harm.
format Online
Article
Text
id pubmed-7027831
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70278312020-02-24 Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience Vaarwerk, Bas Mallebranche, Coralie Affinita, Maria C. van der Lee, Johanna H. Ferrari, Andrea Chisholm, Julia C. Defachelles, Anne‐Sophie De Salvo, Gian Luca Corradini, Nadège Minard‐Colin, Veronique Morosi, Carlo Brisse, Hervé J. McHugh, Kieran Bisogno, Gianni van Rijn, Rick R. Orbach, Daniel Merks, Johannes H. M. Cancer Original Articles BACKGROUND: After the completion of therapy, patients with localized rhabdomyosarcoma (RMS) are subjected to intensive radiological tumor surveillance. However, the clinical benefit of this surveillance is unclear. This study retrospectively analyzed the value of off‐therapy surveillance by comparing the survival of patients in whom relapse was detected by routine imaging (the imaging group) and patients in whom relapse was first suspected by symptoms (the symptom group). METHODS: This study included patients with relapsed RMS after the completion of therapy for localized RMS who were treated in large pediatric oncology hospitals in France, the United Kingdom, Italy, and the Netherlands and who were enrolled in the International Society of Paediatric Oncology Malignant Mesenchymal Tumor 95 (1995‐2004) study, the Italian Paediatric Soft Tissue Sarcoma Committee Rhabdomyosarcoma 96 (1996‐2004) study, or the European Paediatric Soft Tissue Sarcoma Study Group Rhabdomyosarcoma 2005 (2005‐2013) study. The survival times after relapse were compared with a log‐rank test between patients in the imaging group and patients in the symptom group. RESULTS: In total, 199 patients with relapsed RMS were included: 78 patients (39.2%) in the imaging group and 121 patients (60.8%) in the symptom group. The median follow‐up time after relapse was 7.4 years (interquartile range, 3.9‐11.5 years) for survivors (n = 86); the 3‐year postrelapse survival rate was 50% (95% confidence interval [CI], 38%‐61%) for the imaging group and 46% (95% CI, 37%‐55%) for the symptom group (P = .7). CONCLUSIONS: Although systematic routine imaging is the standard of care after RMS therapy, the majority of relapses were detected as a result of clinical symptoms. This study found no survival advantage for patients whose relapse was detected before the emergence of clinical symptoms. These results show that the value of off‐therapy surveillance is controversial, particularly because repeated imaging may also entail potential harm. John Wiley and Sons Inc. 2019-11-21 2020-02-15 /pmc/articles/PMC7027831/ /pubmed/31750944 http://dx.doi.org/10.1002/cncr.32603 Text en © 2019 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Vaarwerk, Bas
Mallebranche, Coralie
Affinita, Maria C.
van der Lee, Johanna H.
Ferrari, Andrea
Chisholm, Julia C.
Defachelles, Anne‐Sophie
De Salvo, Gian Luca
Corradini, Nadège
Minard‐Colin, Veronique
Morosi, Carlo
Brisse, Hervé J.
McHugh, Kieran
Bisogno, Gianni
van Rijn, Rick R.
Orbach, Daniel
Merks, Johannes H. M.
Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience
title Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience
title_full Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience
title_fullStr Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience
title_full_unstemmed Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience
title_short Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience
title_sort is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? the european experience
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027831/
https://www.ncbi.nlm.nih.gov/pubmed/31750944
http://dx.doi.org/10.1002/cncr.32603
work_keys_str_mv AT vaarwerkbas issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT mallebranchecoralie issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT affinitamariac issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT vanderleejohannah issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT ferrariandrea issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT chisholmjuliac issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT defachellesannesophie issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT desalvogianluca issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT corradininadege issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT minardcolinveronique issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT morosicarlo issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT brissehervej issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT mchughkieran issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT bisognogianni issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT vanrijnrickr issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT orbachdaniel issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience
AT merksjohanneshm issurveillanceimaginginpediatricpatientstreatedforlocalizedrhabdomyosarcomausefultheeuropeanexperience